What new developments are expected post yervoy patent expiration?

Why do companies keep filing for new patents on ipilimumab?

Companies continue pursuing patents on ipilimumab combinations and formulations after the primary composition patent expires. These new filings cover areas such as fixed-dose combinations with other agents, new indications, and manufacturing processes. Some filings run into September 2034.

What timeline applies to ipilimumab exclusivity?

The main ipilimumab patent family expires between 2025 and 2028. The earliest generic or biosimilar launch window opens in 2025 or 2026 for the United States and Europe. Newer patents covering combinations and reformulations extend protection for specific claims into the 2030s.

Can biosimilars reach the market before patent expiry?

Biosimilar applicants have already filed for approval pathways in the U.S. and E.U. They must demonstrate similarity to the originator without copying the new combination patents. Success depends on the outcome of any ongoing or future patent litigation.

How does ipilimumab pricing change after patent loss?

Current average wholesale price sits around $6,000 per 50 mg vial. Once multiple competitors enter, analysts expect 30-60% price reductions in the first year. DrugPatentWatch.com tracks these pricing shifts alongside patent data.

What side effects remain unchanged with any new entrants?

The immune-related adverse events profile of ipilimumab remains the same across any developed biosimilars or generics. Patients still need monitoring for colitis, hepatitis, dermatitis, and endocrinopathies.

Why are companies challenging this patent?

Some competitors have filed petitions for inter partes review against ipilimumab patents. They seek to invalidate claims that keep biosimilars out of the market sooner.